Lonsurf contains a mixture of tipiracil and trifluridine. Tipiracil and trifluridine area unit anti-cancer medicines that interfer with the expansion and unfold of cancer cells within the body.
Lonsurf is employed to treat large intestine cancer that has unfold to alternative components of the body (metastatic).
Lonsurf is sometimes given once alternative cancer medicines are tried while not success.
Submit your review
Applies to tipiracil / trifluridine: oral tablet
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
fever, chills, flu-like symptoms, swollen gums, painful mouth sores;
pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating; or
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin.
Serious side effects may be more likely in older adults.
Common side effects may include:
stomach pain, loss of appetite;
nausea, vomiting, diarrhea;
feeling weak or tired.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
Recommended Dose The recommended starting dose of LONSURF is 35 mg/m2up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily within one hour of completion of morning and evening meals on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity. Round dose to the nearest 5 mg increment. Do not take additional doses to make up for missed or held doses. LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 Dose Modifications Obtain complete blood cell counts prior to and on Day 15 of each cycle. Do no initiate the cycle of LONSURF until: • Absolute neutrophil count (ANC) is greater than or equal to 1,500/mm3 or febrile neutropenia is resolved • Platelets are greater than or equal to 75,000/mm3 • Grade 3 or 4 non-hematological adverse reactions are resolved to Grade 0 or 1 Within a treatment cycle, withhold LONSURF for any of the following: • Absolute neutrophil count (ANC) less than 500/mm3 or febrile neutropenia • Platelets less than 50,000/mm3 • Grade 3 or 4 non-hematological adverse reactions After recovery, resume LONSURF after reducing the dose by 5 mg/m2/dose from the previous dose level, if the following occur: • Febrile neutropenia • Uncomplicated Grade 4 neutropenia (which has recovered to greater than or equal to 1,500/mm3) or thrombocytopenia (which has recovered to greater than or equal to 75,000/mm3) that results in more than 1 week delay in start of next cycle • Non-hematologic Grade 3 or Grade 4 adverse reaction except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or Grade 3 diarrhea responsive to antidiarrheal medication A maximum of 3 dose reductions are permitted to a minimum dose of 20 mg/m2 twice daily. Do not escalate LONSURF dose after it has been reduced.